Education
About Us
Working with TipRanks
Follow Us
Oragenics Inc (OGEN)
:OGEN
Top Page
Oragenics
(NYSE MKT:OGEN)
29Underperform
Oragenics (OGEN) vs. S&P 500 (SPY)
Market Cap
$3.87M
Dividend YieldN/A
Average Volume (3M)338.42K
Price to Earnings (P/E)―
Beta (1Y)2.09
Revenue Growth-100.00%
EPS Growth76.55%
CountryUS
Employees3
SectorHealthcare
Sector Strength48
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.85
Shares Outstanding21,475,288
10 Day Avg. Volume261,394
30 Day Avg. Volume338,415
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-10.00
Price to Sales (P/S)0.00
P/FCF Ratio-0.42
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue-36.35
Enterprise Value/Gross Profit-1.96
Enterprise Value/Ebitda-0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Oragenics Business Overview & Revenue Model
Company DescriptionOragenics, Inc. (OGEN) is a biopharmaceutical company focused on the development of novel antibiotics and treatments for infectious diseases. The company operates primarily in the biotechnology sector, with a core emphasis on addressing antibiotic resistance and unmet medical needs through its research and development efforts. Oragenics is known for its proprietary lantibiotic platform, which is designed to create new antibiotics with unique mechanisms of action.
How the Company Makes MoneyOragenics generates revenue primarily through research and development collaborations, grants, and potential milestone payments from strategic partnerships. The company focuses on advancing its product candidates through various stages of clinical trials, aiming to out-license or co-develop these products with larger pharmaceutical companies. Revenue is also derived from government and private funding initiatives that support the development of new antibiotics and treatments for infectious diseases. Long-term, Oragenics aims to commercialize its proprietary products, thereby generating revenue through product sales and royalties.
Oragenics Financial Statement Overview
Summary
Oragenics is facing significant financial challenges, with persistent losses, negative equity, and cash flow issues. The company's financial position is fragile, with minimal revenues and ongoing reliance on financing activities to sustain operations. Improving operational efficiency and generating revenue growth are crucial to enhancing financial stability.Income Statement
The company has experienced declining revenues over the years, with no revenues in 2024 and minimal revenues in previous years. Gross profit margins are negative, indicating cost inefficiencies or low sales volumes. The company has consistently reported negative EBIT and net income, reflecting ongoing unprofitability.10
Very Negative
Balance Sheet
The balance sheet shows a negative stockholders' equity in 2024, indicating potential financial distress. The debt-to-equity ratio is not meaningful due to negative equity, though total liabilities have decreased over time. The company has maintained a high cash balance, which provides some liquidity despite ongoing losses.20
Very Negative
Cash Flow
Operating cash flow has been negative, reflecting cash outflows from operations, though financing activities have provided some cash inflows. Free cash flow is consistently negative, which underscores the challenges in generating sufficient cash to cover operating and potential capital expenditures.25
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 37.65K | 131.52K | 86.99K | 0.00 | Gross Profit |
| 0.00 | -15.45M | 86.85K | 45.75K | -51.70K | EBIT |
| -10.56M | -20.90M | -14.42M | -15.77M | -26.64M | EBITDA |
| -10.56M | -20.88M | -14.23M | -15.65M | -26.37M | Net Income Common Stockholders |
| -10.57M | -20.66M | -14.16M | -15.73M | -26.44M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 864.84K | 3.48M | 11.43M | 27.27M | 17.64M | Total Assets |
| 1.47M | 4.97M | 14.76M | 28.23M | 18.68M | Total Debt |
| 328.53K | 322.51K | 624.53K | 797.21K | 898.92K | Net Debt |
| -536.31K | -3.16M | -10.80M | -26.47M | -16.74M | Total Liabilities |
| 1.68M | 1.80M | 1.75M | 1.74M | 1.84M | Stockholders Equity |
| -211.88K | 3.17M | 13.01M | 26.49M | 16.84M |
| Cash Flow | Free Cash Flow | |||
| -8.60M | -7.29M | -15.36M | -13.51M | -16.95M | Operating Cash Flow |
| -8.60M | -7.29M | -15.23M | -13.47M | -16.95M | Investing Cash Flow |
| 0.00 | -936.28K | -115.52K | -43.88K | 0.00 | Financing Cash Flow |
| 5.98M | 283.88K | -494.92K | 23.14M | 16.32M |
Oragenics Technical Analysis
Neutral
0.20
Price Trends
0.22
Negative
0.27
Negative
0.43
Negative
Market Momentum
>-0.01
Negative
52.59
Neutral
49.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OGEN, the sentiment is Neutral. The current price of 0.2 is above the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.22, and below the 200-day MA of 0.43, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.59 is Neutral, neither overbought nor oversold. The STOCH value of 49.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OGEN.
Oragenics Risk Analysis
Oragenics disclosed 67 risk factors in its most recent earnings report. Oragenics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oragenics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.22B | 3.55 | -44.39% | 2.82% | 15.40% | -0.09% | |
45 Neutral | $1.44M | ― | -87.31% | ― | ― | 6.87% | |
43 Neutral | $4.78M | ― | -50.12% | ― | -1.56% | 5.01% | |
41 Neutral | $5.24M | ― | -522.60% | ― | 19.75% | 95.65% | |
31 Underperform | $3.98M | ― | -2639.52% | ― | ― | 19.58% | |
29 Underperform | $3.87M | ― | -748.05% | ― | -100.00% | 76.55% |
* Healthcare Sector Average
Performance Comparison
OGEN
Oragenics
0.20
-1.44
-87.80%
KZIA
Kazia Therapeutics
3.60
-10.28
-74.06%
TOVX
Theriva Biologics
0.56
-8.72
-93.97%
JAGX
Jaguar Animal Health
6.60
-376.05
-98.28%
XBIO
Xenetic Biosciences
3.06
-0.90
-22.73%
Oragenics Corporate Events
Executive/Board ChangesShareholder MeetingsStock Split
Oragenics Appoints Janet Huffman as CEO and CFO
Neutral
May 2, 2025
On May 2, 2025, Oragenics, Inc. appointed Janet Huffman as the Chief Executive Officer, in addition to her role as Chief Financial Officer, under a new Executive Employment Agreement. This agreement outlines her compensation and severance terms, reflecting the company’s strategic leadership decisions. During the same day, the company’s Annual Meeting saw the re-election of directors and the approval of several proposals, including a reverse stock split and amendments to the company’s Articles of Incorporation and Equity Incentive Plan, indicating a focus on financial restructuring and growth.
Spark’s Take on OGEN Stock
According to Spark, TipRanks’ AI Analyst, OGEN is a Underperform.
Oragenics exhibits significant financial distress, with ongoing unprofitability, negative equity, and cash flow issues, contributing to a low financial performance score. The technical indicators reflect a weak stock momentum, further exacerbating the negative outlook. Valuation metrics are unfavorable due to negative earnings and lack of dividends, highlighting the challenges facing the company. Overall, the stock’s fundamental and technical weaknesses are significant, resulting in a low overall score.
To see Spark’s full report on OGEN stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.